A detailed history of Lindbrook Capital, LLC transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 89 shares of KURA stock, worth $866. This represents 0.0% of its overall portfolio holdings.

Number of Shares
89
Previous 207 57.0%
Holding current value
$866
Previous $4,000 75.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$18.57 - $23.23 $2,191 - $2,741
-118 Reduced 57.0%
89 $1,000
Q2 2024

Jul 31, 2024

BUY
$17.53 - $22.98 $1,788 - $2,343
102 Added 97.14%
207 $4,000
Q1 2024

Apr 25, 2024

BUY
$13.42 - $23.53 $308 - $541
23 Added 28.05%
105 $2,000
Q4 2023

Jan 31, 2024

BUY
$7.58 - $14.38 $621 - $1,179
82 New
82 $1,000
Q3 2023

Oct 25, 2023

SELL
$8.44 - $11.86 $2,067 - $2,905
-245 Closed
0 $0
Q2 2023

Jul 28, 2023

SELL
$9.62 - $13.99 $8,706 - $12,660
-905 Reduced 78.7%
245 $2,000
Q1 2023

Apr 26, 2023

BUY
$10.71 - $14.6 $7,657 - $10,439
715 Added 164.37%
1,150 $14,000
Q4 2022

Jan 24, 2023

SELL
$11.23 - $16.9 $2,571 - $3,870
-229 Reduced 34.49%
435 $0
Q3 2022

Nov 10, 2022

SELL
$12.01 - $19.45 $912 - $1,478
-76 Reduced 10.27%
664 $9,000
Q2 2022

Aug 01, 2022

SELL
$10.71 - $18.33 $631 - $1,081
-59 Reduced 7.38%
740 $14,000
Q1 2022

Apr 21, 2022

SELL
$11.78 - $16.98 $12,710 - $18,321
-1,079 Reduced 57.45%
799 $13,000
Q4 2021

Jan 18, 2022

BUY
$12.22 - $19.57 $21,641 - $34,658
1,771 Added 1655.14%
1,878 $26,000
Q1 2020

Apr 22, 2020

BUY
$6.45 - $14.04 $690 - $1,502
107 New
107 $1,000

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $652M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.